Literature DB >> 19244100

The interleukin-11 receptor alpha as a candidate ligand-directed target in osteosarcoma: consistent data from cell lines, orthotopic models, and human tumor samples.

Valerae O Lewis1, Michael G Ozawa, Michael T Deavers, Guiying Wang, Tomo Shintani, Wadih Arap, Renata Pasqualini.   

Abstract

The interleukin-11 receptor alpha (IL-11Ralpha) is a functional target in bone metastasis. However, its role in primary bone tumors has not been established. As such, here, we evaluated IL-11Ralpha as a candidate target in primary and metastatic human osteosarcoma. First, in an orthotopic mouse model, we showed that IL-11Ralpha protein is markedly expressed in primary osseus and pulmonary metastatic osteosarcoma but absent from control normal tibia and lung. Moreover, systemic administration of an IL-11Ralpha-targeting phage displaying the cyclic nonapeptide CGRRAGGSC resulted in strong and selective accumulation of IL-11Ralpha-homing phage particles in the osteosarcoma but not in several control organs. Finally, IL-11Ralpha expression in a large panel of human primary and metastatic osteosarcoma samples was remarkably consistent with the observations in the orthotopic mouse model. These data establish IL-11Ralpha as a candidate target in human osteosarcoma and provide leads for the development of novel imaging and therapeutic agents for the management of this malignant tumor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19244100     DOI: 10.1158/0008-5472.CAN-08-4845

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  Genetically modified T cells targeting interleukin-11 receptor α-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases.

Authors:  Gangxiong Huang; Ling Yu; Laurence Jn Cooper; Mario Hollomon; Helen Huls; Eugenie S Kleinerman
Journal:  Cancer Res       Date:  2011-11-10       Impact factor: 12.701

Review 2.  Adoptive Cell Therapy in Treating Pediatric Solid Tumors.

Authors:  Mekdem Tesfaye; Barbara Savoldo
Journal:  Curr Oncol Rep       Date:  2018-08-01       Impact factor: 5.075

3.  BMTP-11 is active in preclinical models of human osteosarcoma and a candidate targeted drug for clinical translation.

Authors:  Valerae O Lewis; Eswaran Devarajan; Marina Cardó-Vila; Dafydd G Thomas; Eugenie S Kleinerman; Serena Marchiò; Richard L Sidman; Renata Pasqualini; Wadih Arap
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-11       Impact factor: 11.205

4.  Autocrine production of IL-11 mediates tumorigenicity in hypoxic cancer cells.

Authors:  Barbara Onnis; Nicole Fer; Annamaria Rapisarda; Victor S Perez; Giovanni Melillo
Journal:  J Clin Invest       Date:  2013-03-15       Impact factor: 14.808

5.  A role for transcription factor STAT3 signaling in oncogene smoothened-driven carcinogenesis.

Authors:  Dongsheng Gu; Qipeng Fan; Xiaoli Zhang; Jingwu Xie
Journal:  J Biol Chem       Date:  2012-09-19       Impact factor: 5.157

6.  Non-core region modulates interleukin-11 signaling activity: generation of agonist and antagonist variants.

Authors:  Saeko Yanaka; 中冴子 谷; Emiko Sano; 野恵海子 佐; Norio Naruse; 瀬紀男 成; Kin-Ichiro Miura; 浦謹一郎 三; Mutsumi Futatsumori-Sugai; ツ森ー菅井睦美 二; Jose M M Caaveiro; Kouhei Tsumoto; 本浩平 津
Journal:  J Biol Chem       Date:  2010-12-07       Impact factor: 5.157

7.  Adoptive T-Cell Therapy for Solid Tumors.

Authors:  Oladapo Yeku; Xinghuo Li; Renier J Brentjens
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

8.  Interleukin 11 is upregulated in uterine lavage and endometrial cancer cells in women with endometrial carcinoma.

Authors:  Joanne Yap; Lois A Salamonsen; Tom Jobling; Peter K Nicholls; Evdokia Dimitriadis
Journal:  Reprod Biol Endocrinol       Date:  2010-06-17       Impact factor: 5.211

Review 9.  Targeting of drugs and nanoparticles to tumors.

Authors:  Erkki Ruoslahti; Sangeeta N Bhatia; Michael J Sailor
Journal:  J Cell Biol       Date:  2010-03-15       Impact factor: 10.539

Review 10.  Ligand-targeted theranostic nanomedicines against cancer.

Authors:  Virginia J Yao; Sara D'Angelo; Kimberly S Butler; Christophe Theron; Tracey L Smith; Serena Marchiò; Juri G Gelovani; Richard L Sidman; Andrey S Dobroff; C Jeffrey Brinker; Andrew R M Bradbury; Wadih Arap; Renata Pasqualini
Journal:  J Control Release       Date:  2016-01-06       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.